Field researchers constructed a model to subsidize essential goods for low-income communities in crisis, and profit in recovery
Researchers aim to help the agency, drug companies and patients better understand the complex authorization process
Backers like to offer suggestions to a not-quite-finished product
Sales forecasting improves markedly as firms participate in standard setting organizations
R&D outlays and patents alone don’t effectively measure corporate creativity
Pharma companies less likely to disclose critical drug information than public institutions
Dedicated FDA staff guide companies during design of clinical trials
New product filings to FDA included stronger safety features and larger technological advances
Pharma companies seek OK for limited use, then expand sales through off-label prescribing, saving millions
Corporate embrace of safety and experience in technical measurement is crucial determinant